Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Nicolas

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
Digestive Diseases and Sciences|July 1, 1996
Crohn's disease and vitamin B12 metabolismD Lambert, S Benhayoun, C Adjalla, et al.
The Biochemical Journal|September 24, 1999
Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptorsF Cogé, S P Guenin, A Renouard-Try, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The British Journal of Nutrition|February 15, 2001
5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohortA Chango, G Potier De Courcy, F Boisson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Regulatory Peptides|November 5, 1998
NPY receptor subtypes involved in the contraction of the proximal colon of the ratM Félétou, M Rodriguez, P Beauverger, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
Digestive Diseases and Sciences|July 1, 1996
Crohn's disease and vitamin B12 metabolismD Lambert, S Benhayoun, C Adjalla, et al.
The Biochemical Journal|September 24, 1999
Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptorsF Cogé, S P Guenin, A Renouard-Try, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 1998
S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and racloprideM J Millan, A Newman-Tancredi, M Brocco, et al.
Synapse (New York, N.Y.)|December 28, 1999
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive statesM J Millan, A Newman-Tancredi, V Audinot, et al.
The British Journal of Nutrition|February 15, 2001
5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohortA Chango, G Potier De Courcy, F Boisson, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 18, 2001
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterizationM J Millan, D Cussac, G Milligan, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Regulatory Peptides|November 5, 1998
NPY receptor subtypes involved in the contraction of the proximal colon of the ratM Félétou, M Rodriguez, P Beauverger, et al.
Pageof 20